Search

Displaying results 1281 - 1290 of 6074 in total
  1. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. … The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424]

  2. Drug

    Nomegestrol acetate

    go.drugbank.com/drugs/DB13981
    Approved

    Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders.

    Categories: Hormonal Contraceptives for Systemic Use
  3. Drug

    Clobazam

    go.drugbank.com/drugs/DB00349
    ApprovedIllicitInvestigational

    [A256958] In 2005, clobazam also received approval from Health Canada as an add-on therapy for generalized tonic-clonic, myoclonic, and focal impaired awareness seizures.[A256978] … [A521,A522] In October 21, 2011, the FDA approved clobazam as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children aged two years and older.

  4. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain.

    Categories: Topical Products for Joint and Muscular Pain
  6. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    This type of virus is vastly used as vectors for gene therapy because they can infect dividing and quiescent cell integrating just the carried genes into the host genome without fully integrating into … When used in genetic therapy, this virus is modified for the elimination of its negligible integrative capacity by the removal of *rep* and *cap* and the insertion of the desired gene with its promoter

  7. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.

  8. Drug

    Gentian violet cation

    go.drugbank.com/drugs/DB00406
    Approved

    A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  9. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … Eteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene, which codes for dystrophin, that

  10. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    [A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea.